文献速递新发突发、热带与寄生虫病

索磷布韦/达拉他韦或利巴韦林治疗重症COVID-19的影响

The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

索磷布韦/达拉他韦组中位住院时间5天,利巴韦林组9天;死亡率分别为6%(2/35)和33%(9/27),相对风险0.17(95%CI 0.04-0.73,P=0.02)。

要点

  • 索磷布韦/达拉他韦组死亡风险显著低于利巴韦林组(RR 0.17)。
  • 索磷布韦/达拉他韦组中位住院时间5天,短于利巴韦林组的9天。
  • 需更大规模试验进一步验证。

核心结论

  • 在重症COVID-19患者中,索磷布韦/达拉他韦较利巴韦林显著降低死亡风险并缩短住院时间。

主要发现

  • 索磷布韦/达拉他韦组中位住院时间5天,利巴韦林组9天。
  • 索磷布韦/达拉他韦组死亡2/35(6%),利巴韦林组死亡9/27(33%)。
  • 索磷布韦/达拉他韦组死亡相对风险0.17(95%CI 0.04-0.73,P=0.02),需治疗人数3.6(95%CI 2.1-12.1,P<0.01)。

临床怎么用

  • 对于重症COVID-19患者,索磷布韦/达拉他韦可能作为降低死亡风险的治疗选择,但需更大规模试验确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Sofosbuvir and daclatasvir are direct-acting antivirals highly effective against hepatitis C virus. There is some in silico and in vitro evidence that suggests these agents may also be effective against SARS-CoV-2. This trial evaluated the effectiveness of sofosbuvir in combination with daclatasvir in treating patients with COVID-19. METHODS: Patients with a positive nasopharyngeal swab for SARS-CoV-2 on RT-PCR or bilateral multi-lobar ground-glass opacity on their chest CT and signs of severe COVID-19 were included. Subjects were divided into two arms with one arm receiving ribavirin and the other receiving sofosbuvir/daclatasvir. All participants also received the recommended national standard treatment which, at that time, was lopinavir/ritonavir and single-dose hydroxychloroquine. The primary endpoint was time from starting the medication until discharge from hospital with secondary endpoints of duration of ICU stay and mortality. RESULTS: Sixty-two subjects met the inclusion criteria, with 35 enrolled in the sofosbuvir/daclatasvir arm and 27 in the ribavirin arm. The median duration of stay was 5 days for the sofosbuvir/daclatasvir group and 9 days for the ribavirin group. The mortality in the sofosbuvir/daclatasvir group was 2/35 (6%) and 9/27 (33%) for the ribavirin group. The relative risk of death for patients treated with sofosbuvir/daclatasvir was 0.17 (95% CI 0.04-0.73, P = 0.02) and the number needed to treat for benefit was 3.6 (95% CI 2.1-12.1, P < 0.01). CONCLUSIONS: Given these encouraging initial results, and the current lack of treatments proven to decrease mortality in COVID-19, further investigation in larger-scale trials seems warranted.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Eslami G, Mousaviasl S, Radmanesh E, et al. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19. J Antimicrob Chemother. 2020. PMID: 32812051. doi:10.1093/jac/dkaa331

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。